10 February, 2021
A new molecular test detects genetic abnormalities in tumours and improves customised cancer diagnosis and treatment
At the Grupo Hospital Clínic, we have a new option for diagnosis of advanced cancer. It is a new test using Next Generation Sequencing (NGS) technology which, by analysing the tumour’s DNA and RNA, detects multiple genetic abnormalities in 52 of your genes. This new cancer diagnostic test allows your treatment to be further customised. In addition, it improves current tests for the diagnosis of lung, colon and rectal cancer and melanoma.
YOU MAY BE INTERESTED IN…
PIONEERS IN THE USE OF GENETIC TESTING TO DIAGNOSE CANCER
The Grupo Hospital Clínic is a pioneer in the implementation and use of genetic and molecular testing to diagnose cancer. In 2016, it introduced the routine use of a 22-gene genetic test for the diagnosis of lung, colon and rectalcancer and melanoma. This new test analyses 52 genes for which there is a specific approved treatment or that will open the doors to participation in a clinical trial.
IMPROVES CUSTOMISED CANCER TREATMENT
This new molecular test detects all currently treatable genetic abnormalities, but also those that may be treatable in the future. Expanding the panel of analysed genes ensures the detection of even more genetic abnormalities with potential, known or future treatment. As stated by Dr Aleix Prat, head of the Clinic’s Medical Oncology Service and barnaclínic+ oncologist, “this new genetic test for cancer diagnosis offers us a more complete picture of tumour biology. Thanks to this, we can offer a more appropriate treatment for each case”.
Furthermore, the routine application of this new test will allow us to gain more experience with diagnostic technology, which will help to improve the technique and aspire to higher levels of quality of care.
“This new genetic test for the diagnosis of cancer offers us a more complete picture of tumour biology. Thanks to this, we can offer a more appropriate treatment for each case”
YOU MAY BE INTERESTED IN…
THE GRUPO HOSPITAL CLÍNIC, AT THE FOREFRONT IN THE MOLECULAR DIAGNOSIS OF CANCER
With the implementation of this new test, the Grupo Hospital Clínic Medical Oncology Service is positioned at the forefront of the clinical application of the molecular diagnosis of cancer. The technology it will use, the number of genes analysed and the types of cancer studied routinely (lung, breast, colon and rectal cancer, melanoma, bile duct, pancreas, thyroid, salivary glands and bladder cancer) place it at the forefront in the national setting.